CLINICAL RESEARCH: ACUTE CORONARY SYNDROMES
A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial
Gilles Montalescot, MD, PhD*,*,
Georges Sideris, MD ,
Catherine Meuleman, MD ,
Claire Bal-dit-Sollier, MB ,
Nicolas Lellouche, MD||,
Ph. Gabriel Steg, MD¶,
Michel Slama, MD#,
Olivier Milleron, MD**,
Jean-Philippe Collet, MD, PhD*,
Patrick Henry, MD,
Farzin Beygui, MD, PhD*,
Ludovic Drouet, MD, PhD for the ALBION Trial Investigators
* Institut de Cardiologie–Pitié-Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris (APHP)
Service de Cardiologie–Lariboisiére University Hospital, APHP
Service de Cardiologie–Saint-Antoine University Hospital, APHP
Laboratoire d'Hémostase–Lariboisière University Hospital, APHP
|| Service de Cardiologie–Henri-Mondor University Hospital, APHP
¶ Service de Cardiologie–Hôpital Bichat-Claude Bernard, APHP
# Service de Cardiologie–Antoine Béclère University Hospital, APHP
** Service de Cardiologie–Ambroise Paré University Hospital, APHP, Paris, France
Manuscript received September 26, 2005;
revised manuscript received April 20, 2006,
accepted April 25, 2006.
* Reprint requests and correspondence to: Dr. Gilles Montalescot, Institut de Cardiologie, Bureau 2-236, Pitié-Salpêtrière Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France. (Email: gilles.montalescot{at}psl.aphp.fr).
OBJECTIVES: We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs).
BACKGROUND: Administration of a 300-mg clopidogrel LD is beneficial in situations requiring rapid platelet inhibition. Whether higher LDs can provide further benefits remains unknown.
METHODS: Patients (n = 103) with non–ST-segment elevation acute coronary syndromes were randomized to receive a 300-mg, 600-mg, or 900-mg clopidogrel LD, given on top of other standard therapy (including acetylsalicylic acid). The main outcome measure was inhibition of adenosine diphosphate-induced inhibition of platelet aggregation (IPA); inhibition of platelet activation, inflammatory markers, troponin I release, and major adverse cardiac events also were evaluated; all measures were blindly evaluated.
RESULTS: Compared with the 300-mg LD, greater doses were associated with significantly greater platelet inhibition, with dose-effect relationships observed for onset of action, maximal plateau, 24-h areas under the curves of IPA, and rates of low IPA (<10% at 6 h), using 20 µmol/l major adverse cardiac events. A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y12 receptor inhibition. Similar but nonsignificant trends were observed for troponin release and major adverse cardiac events. Bleeding rates were similar in each group.
CONCLUSIONS: In low-to-moderate risk patients with non–ST-elevation acute coronary syndromes, clopidogrel LDs >300 mg provide a faster onset of action, a higher IPA plateau, and greater reductions in platelet activation during the first 24 h. A 900-mg LD may induce a greater antiplatelet effect than 600 mg, when compared with the standard 300-mg regimen. These findings require further clinical confirmation.
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | ASA = acetylsalicylic acid | | AUC = area under the inhibition of platelet aggregation curve | | GP = glycoprotein | | IPA = inhibition of platelet aggregation | | LD = loading dose | | LMWH = low molecular weight heparin | | MACE = major adverse cardiac events | | MFI = median fluorescence intensity | | NSTE-ACS = non–ST-segment elevation acute coronary syndrome | | PA = platelet aggregation | | PAI = plasminogen activator inhibitor | | PCI = percutaneous coronary intervention | | PGE1 = prostaglandin E1 | | sCD40L = soluble CD40 ligand | | VASP = vasodilator-stimulated phosphoprotein | | vWF Ag = von Willebrand factor antigen |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2006 48: A39-A40.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. W. Eikelboom, J. Hirsh, F. A. Spencer, T. P. Baglin, and J. I. Weitz
Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest,
February 1, 2012;
141(2_suppl):
e89S - e119S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, et al.
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
Eur. Heart J.,
December 1, 2011;
32(23):
2999 - 3054.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Comin and D. Kallmes
Clopidogrel (Plavix)
AJNR Am. J. Neuroradiol.,
December 1, 2011;
32(11):
2002 - 2004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Jeong, U. S. Tantry, I.-S. Kim, J.-S. Koh, T. J. Kwon, Y. Park, S.-J. Hwang, K. P. Bliden, C. H. Kwak, J.-Y. Hwang, et al.
Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin
Circ Cardiovasc Interv,
December 1, 2011;
4(6):
585 - 594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Skolnick, M. Shenouda, N. M. Khutoryansky, A. E. Pusateri, D. Gabriel, and M. E. Carr
Reversal of Clopidogrel-Induced Bleeding with rFVIIa in Healthy Subjects: A Randomized, Placebo-Controlled, Double-Blind, Exploratory Study
Anesth. Analg.,
October 1, 2011;
113(4):
703 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Montalescot
Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease
Clinical and Applied Thrombosis/Hemostasis,
August 1, 2011;
17(4):
371 - 380.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, F. Castriota, S. De Servi, J. Kubica, and G. De luca
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials
QJM,
July 1, 2011;
104(7):
561 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, M. Miccoli, J. Marchesini, F. Bernardi, R. Ferrari, and M. Valgimigli
Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention: Relationship With Gene Polymorphisms and Clinical Outcome
J. Am. Coll. Cardiol.,
June 21, 2011;
57(25):
2474 - 2483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, A. M. Lincoff, et al.
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Am. Coll. Cardiol.,
May 10, 2011;
57(19):
e215 - e367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, A. M. Lincoff, et al.
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
May 10, 2011;
57(19):
1920 - 1959.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2011 Writing Group Members, R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, et al.
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
May 10, 2011;
123(18):
2022 - 2060.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
May 10, 2011;
123(18):
e426 - e579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Weber, D. L. Bhatt, D. M. Brennan, G. J. Hankey, S. R. Steinhubl, S. C. Johnston, G. Montalescot, K.-H. Mak, K. A. A. Fox, D. J. Easton, et al.
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial
Heart,
April 15, 2011;
97(8):
626 - 631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, J. J. Badimon, J. F. Saucedo, A. L. Frelinger, A. D. Michelson, J. A. Jakubowski, B. Zhu, C. K. Ojeh, B. A. Baker, and M. B. Effron
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
Eur. Heart J.,
April 1, 2011;
32(7):
838 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I.-S. Kim, Y.-H. Jeong, Y. Park, K.-S. Park, S.-E. Yun, J.-R. Park, S.-J. Hwang, E.-H. Koh, C. H. Kwak, J.-Y. Hwang, et al.
Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
381 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet, J.-S. Hulot, G. Anzaha, A. Pena, T. Chastre, C. Caron, J. Silvain, G. Cayla, A. Bellemain-Appaix, J.-B. Vignalou, et al.
High Doses of Clopidogrel to Overcome Genetic Resistance: The Randomized Crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
392 - 402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Perry
Clopidogrel hyporesponsiveness and the FDA boxed warning: Detection and management of patients with genetic polymorphisms
Am. J. Health Syst. Pharm.,
March 15, 2011;
68(6):
529 - 532.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Held, N. Asenblad, J. P. Bassand, R. C. Becker, C. P. Cannon, M. J. Claeys, R. A. Harrington, J. Horrow, S. Husted, S. K. James, et al.
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
J. Am. Coll. Cardiol.,
February 8, 2011;
57(6):
672 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Silvain, A. Bellemain-Appaix, O. Barthelemy, F. Beygui, J.-P. Collet, and G. Montalescot
Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7
Circ Cardiovasc Interv,
February 1, 2011;
4(1):
95 - 103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Goodwin, A. R. Desilets, and K. C. Willett
Thienopyridines in Acute Coronary Syndrome
Ann. Pharmacother.,
February 1, 2011;
45(2):
207 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Siller-Matula, K. Huber, G. Christ, K. Schror, J. Kubica, H. Herkner, and B. Jilma
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Heart,
January 15, 2011;
97(2):
98 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Silvain, A. Pena, G. Cayla, D. Brieger, A. Bellemain-Appaix, T. Chastre, J.-B. Vignalou, F. Beygui, O. Barthelemy, J.-P. Collet, et al.
Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study
Eur. Heart J.,
November 2, 2010;
31(22):
2816 - 2821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bellemain-Appaix, D. Brieger, F. Beygui, J. Silvain, A. Pena, G. Cayla, O. Barthelemy, J.-P. Collet, and G. Montalescot
New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention: A Meta-Analysis
J. Am. Coll. Cardiol.,
November 2, 2010;
56(19):
1542 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, D. R. Holmes Jr, G. J. Dehmer, S. Kaul, D. Leifer, P. T. O'Gara, and C. M. Stein
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
Circulation,
August 3, 2010;
122(5):
537 - 557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Buch, B. D. Prendergast, and R. F. Storey
Antiplatelet therapy and vascular disease: an update
Therapeutic Advances in Cardiovascular Disease,
August 1, 2010;
4(4):
249 - 275.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Wada, S. Rohatagi, D. Small, K. J. Winters, and D. E. Salazar
Correlation of Inhibition of Platelet Aggregation With Cardiovascular and Bleeding Outcomes in Acute Coronary Syndromes
J. Clin. Pharmacol.,
August 1, 2010;
50(8):
904 - 913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, G. J. Dehmer, S. Kaul, D. Leifer, P. T. O'Gara, and C. M. Stein
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
July 20, 2010;
56(4):
321 - 341.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Jeong, I.-S. Kim, Y. Park, M.-K. Kang, J.-S. Koh, S.-J. Hwang, C. H. Kwak, and J.-Y. Hwang
Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day: Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
731 - 741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mehran, S. J. Pocock, E. Nikolsky, T. Clayton, G. D. Dangas, A. J. Kirtane, H. Parise, M. Fahy, S. V. Manoukian, F. Feit, et al.
A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
June 8, 2010;
55(23):
2556 - 2566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Lamas, E. Escolar, and D. P. Faxon
Review Article: Examining Treatment of ST-Elevation Myocardial Infarction: The Importance of Early Intervention
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2010;
15(1):
6 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Schulz, J. Mehilli, G. Ndrepepa, F.-J. Neumann, K. A. Birkmeier, S. Kufner, G. Richardt, P. B. Berger, A. Schomig, A. Kastrati, et al.
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial
Eur. Heart J.,
March 1, 2010;
31(5):
582 - 587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fiorella
Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel.
JNIS,
March 1, 2010;
2(1):
44 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bellemain-Appaix, G. Montalescot, J. Silvain, O. Barthelemy, F. Beygui, J.-P. Collet, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, et al.
Slow Response to Clopidogrel Predicts Low Response
J. Am. Coll. Cardiol.,
February 23, 2010;
55(8):
815 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Gurbel and U. S. Tantry
Combination Antithrombotic Therapies
Circulation,
February 2, 2010;
121(4):
569 - 583.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Pinto
A 43-Year-Old Man With Angina, Elevated Troponin, and Lateral ST Depression: Management of Acute Coronary Syndromes
JAMA,
January 6, 2010;
303(1):
54 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mahmoudi and N. Curzen
Chapter 15 Percutaneous coronary intervention in non-ST elevation acute coronary syndrome
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Hobson and N. Curzen
Chapter 22 Current status of oral antiplatelet therapies
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Myat and T. Gershlick
Chapter 24 The contemporary use of antiplatelet therapy in interventional cardiology
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Eur. Heart J.,
November 2, 2009;
30(22):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1438 - 1446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano
Antithrombotics in Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
September 8, 2009;
54(11):
969 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet and G. Montalescot
Review: Platelet Function Testing and Implications for Clinical Practice
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
157 - 169.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. O'Donoghue, E. M. Antman, E. Braunwald, S. A. Murphy, P. G. Steg, A. Finkelstein, W. F. Penny, V. Fridrich, C. H. McCabe, M. S. Sabatine, et al.
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis
J. Am. Coll. Cardiol.,
August 18, 2009;
54(8):
678 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J.,
August 2, 2009;
30(16):
1964 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Witkowski, P. Maciejewski, W. Wasek, L. A. Malek, M. Niewada, B. Kaminski, J. Drzewiecki, M. Kosmider, J. Kubica, W. Ruzyllo, et al.
Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality
Eur. Heart J.,
July 2, 2009;
30(14):
1736 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart,
June 1, 2009;
95(11):
861 - 865.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Tousoulis, A. Briasoulis, S. S Dhamrait, C. Antoniades, and C. Stefanadis
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Heart,
May 1, 2009;
95(10):
850 - 858.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Hamm, H. Mollmann, J.-P. Bassand, and F. van de Werf
CHAPTER 16 Acute Coronary Syndromes
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al.
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:
Eur. Heart J.,
December 1, 2008;
29(23):
2909 - 2945.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gladding, M. Webster, I. Zeng, H. Farrell, J. Stewart, P. Ruygrok, J. Ormiston, S. El-Jack, G. Armstrong, P. Kay, et al.
The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
612 - 619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
628 - 630.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.-P. Collet, G. Montalescot, J.-P. Cazenave, M.-C. Dickele, J.-P. Monassier, and C. Gachet
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention: Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study
J. Am. Coll. Cardiol. Intv.,
December 1, 2008;
1(6):
631 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Williams and J. D. Abbott
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Circulation,
September 16, 2008;
118(12):
1219 - 1222.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al.
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study
Circulation,
September 16, 2008;
118(12):
1225 - 1233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bonello, L. Camoin-Jau, F. Dignat-George, and F. Paganelli
A threshold of platelet reactivity for ischaemic events?
Eur. Heart J.,
September 1, 2008;
29(17):
2185 - 2186.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C Coons and S. Battistone
2007 Guideline Update for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction: Focus on Antiplatelet and Anticoagulant Therapies
Ann. Pharmacother.,
July 1, 2008;
42(7):
989 - 1001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Widimsky, Z. Motovska, S. Simek, P. Kala, R. Pudil, F. Holm, R. Petr, D. Bilkova, H. Skalicka, P. Kuchynka, et al.
Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
Eur. Heart J.,
June 2, 2008;
29(12):
1495 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hjemdahl
Should we monitor platelet function during antiplatelet therapy?
Heart,
June 1, 2008;
94(6):
685 - 687.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
Heart,
June 1, 2008;
94(6):
743 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
199S - 233S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
670S - 707S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D3 - D11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, M.-C. Simeoni, P. Barragan, F. Dignat-George, and F. Paganelli
Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study
J. Am. Coll. Cardiol.,
April 8, 2008;
51(14):
1404 - 1411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Comerota and S. Thakur
Management of Anticoagulation and Platelet Inhibition in Reconstructive Vascular Surgery
Vascular,
April 2, 2008;
16(suppl_1):
S48 - S54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens: Results From the PREPAIR Randomized Study
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1066 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Comerota and S. Thakur
Antiplatelet Therapy for Vascular Interventions
Perspectives in Vascular Surgery and Endovascular Therapy,
March 1, 2008;
20(1):
28 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
s33 - s38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies: The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters, and A. Siegbahn
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Eur. Heart J.,
January 1, 2008;
29(1):
21 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and K. Huber
Antiplatelet therapy in percutaneous coronary intervention
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A13 - A20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storey
Variability of response to antiplatelet therapy
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A21 - A27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gachet and B. Aleil
Testing antiplatelet therapy
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A28 - A34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al.
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial
Circulation,
December 18, 2007;
116(25):
2923 - 2932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1386 - 1395.
[Full Text]
[PDF]
|
|
|
|
